Gene: MOXD1
Official Full Name: monooxygenase DBH like 1provided by HGNC
Gene Summary: Predicted to enable copper ion binding activity and dopamine beta-monooxygenase activity. Predicted to be involved in dopamine catabolic process; norepinephrine biosynthetic process; and octopamine biosynthetic process. Part of endoplasmic reticulum membrane. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO28498 | MOXD1 Knockout cell line (HEK293) | Human | MOXD1 | 1:3~1:6 | Negative | Online Inquiry |
KO28499 | MOXD1 Knockout cell line (A549) | Human | MOXD1 | 1:3~1:4 | Negative | Online Inquiry |
MOXD1 Gene Knockout Cell Lines are genetically engineered cell lines that have had the MOXD1 gene specifically disrupted to elucidate its function and role in various biological processes. The MOXD1 gene encodes for a monooxygenase enzyme that is implicated in several metabolic pathways, including those related to lipid metabolism and oxidative stress responses. By knocking out this gene, researchers can investigate how its absence affects cellular functions, providing critical insights into its physiological relevance and potential pathological implications.
These cell lines are invaluable tools for studying the mechanisms through which MOXD1 participates in cellular processes. Researchers can perform gene expression analyses, signaling pathway investigations, and functional assays to understand the impact of MOXD1 on cell proliferation, apoptosis, and metabolic regulation. This can lead to advancements in understanding diseases linked to metabolic dysregulation, including obesity, cardiovascular diseases, and diabetes, thereby holding significant promise for therapeutic development.
The utility of MOXD1 Gene Knockout Cell Lines in both basic and applied research contexts distinguishes them from standard wild-type cell lines. Their precise genetic modification allows for the reliable and repeatable assessment of the MOXD1 function, offering clear advantages in experimental reproducibility and data reliability. This specificity positions them as superior options compared to less targeted approaches, such as using pharmacological inhibitors or siRNA knockdown strategies.
These knockout cell lines serve as a critical resource for researchers and clinicians aiming to translate basic science into clinical applications, enabling deeper discoveries that could lead to the development of targeted therapies. With our commitment to providing high-quality biological products, our company brings expertise in genetic engineering and cell line development, ensuring that users receive exceptional quality and performance in their research endeavors.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.